Zobrazeno 51 - 60
of 518
pro vyhledávání: ''
Autor:
Tanios Bekaii-Saab, Errin Samuelsz, Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Mark G. Erlander, Heinz-Josef Lenz
Publikováno v:
Cancer Research. 80:CT235-CT235
Background: Chemotherapy in combination with targeted agents are standard-of-care options for patients for mCRC with response rates >50% in first line. In the second line setting, efficacy of chemotherapy and targeted agents are much lower with respo
Autor:
Hee-Joon Chung, Soohyeon Lee, Yeul Hong Kim, Kyong Hwa Park, Won Jin Chang, Yoon Ji Choi, Jae Sook Sung, Juwon Kim
Publikováno v:
Cancer Research. 80:3620-3620
The K-MASTER cancer precision medicine diagnosis and treatment enterprise (K-MASTER project) is a precision medicine cancer treatment clinical trial platform, which uses NGS assay to screen the actionable mutations in 10,000 Korean patients with refr
Autor:
Pasi A. Jänne, Christine A. Lydon, Lynette M. Sholl, Mizuki Nishino, Emily Chambers, Natalie I. Vokes, Eliezer M. Van Allen, Tom C. Nguyen
Publikováno v:
Cancer Research. 80:5882-5882
Background: Oncogenic mutations in EGFR are powerful biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, there remains significant heterogeneity in duration of response to therapy and overa
Autor:
Lao H. Saal, Jari Häkkinen, Christer Larsson, Cecilia Hegardt, Anna Ehinger, Sofia Gruvberger, Malin Dahlgren, Christian Brueffer, Anthony M. George, Johan Vallon-Christersson, Åke Borg, Sergii Gladchuk, Martin Malmberg, Yilun Chen, Niklas Loman, Lisa Rydén
Publikováno v:
Cancer Research. 80:CT074-CT074
Background: More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene ESR1), the most important factor for directing anti-estrogenic endocrine therapy. Although mutation in ESR1 is known as a
Publikováno v:
Cancer Research. 80:1324-1324
Background: Alterations in MET exon 14 (METex14) and its flanking intronic regions have been identified in a variety of cancers, and suggested to cause enhanced MET activity and oncogenesis. Clinical evidences suggested that patients with METex14 alt
Publikováno v:
Cancer Prevention Research. 13:A46-A46
Purpose: We previously showed diet-induced obesity (DIO) increases (and calorie restriction decreases) systemic markers of inflammation and azoxymethane (AOM)-induced colon carcinogenesis in FVB/N mice. Our current study examines whether moderate wei
Autor:
Temitope O. Keku, Hanna K. Sanoff, Sushant A. Patil, Michael S. Lee, Kelli Hammond, Todd Auman, Ganiraju C. Manyam, Sara R. Selitsky, Scott Kopetz, Joel S. Parker, Federico Innocenti, Amber N. McCoy
Publikováno v:
Cancer Research. 80:A03-A03
Background: F. nucleatum is an oral anaerobe aberrantly found in up to 43% of CRCs. F. nucleatum presence is associated with additional known prognostic variables, including BRAF mutation and immune infiltration. In nonmetastatic CRC, F. nucleatum is
Autor:
Ming-Yang Wang, Kien Thiam Tan, An Hsu, Ming-Shen Dai, Dwang-Ying Chang, Yen-Shen Lu, De-Wei Zhuo, Shu-Han Chang, Ling-Yi Huang, Ching-Hung Lin, I-Chun Chen, Tom Wei-Wu Chen, Ann-Lii Cheng, Yen-Jung Lu
Publikováno v:
Cancer Research. 80:P5-01
Background: With more hormonal therapies (HT) based treatment (tx) available, predictive markers that could lead to a selection of the optimal tx is necessary. The predictive role of ctDNA mutations in ER+/HER2- MBC after prior HT is less well charac
Autor:
Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne
Publikováno v:
Clinical Cancer Research. 21:2530-2537
Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino
Autor:
William J. Irvin, William T. Barry, Eric P. Winer, Sara M. Tolaney, Chau T. Dang, Brandelyn N. Pitcher, Charles M. Perou, Lisa A. Carey, Elaine R. Mardis, Matthew D. Wilkerson, Clifford A. Hudis, Katherine A. Hoadley, Ian E. Krop, Donald A. Berry, Norah Lynn Henry, Joel S. Parker
Publikováno v:
Cancer Research. 75:S3-06
Background: In CALGB 40601, the HER2-Enriched (HER2-E) molecular subtype had significantly higher pathologic complete response (pCR) rates regardless of treatment arm (single HER2-targeting with T+L or T+H, dual targeting with T+H+L) (Carey et al, AS